Search
Bayer HealthCare Links
Clinical trials
Information about clinical studies is available at database of
News
-
2013-05-20 | Worldnews
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
2013-05-20 | Worldnews
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
-
2013-05-17 | Worldnews
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
2013-05-17 | Worldnews
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
Bayer HealthCare has filed the oral investigational drug riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) for regulatory approval in Japan. more
-
2013-05-16 | Worldnews
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
2013-05-16 | Worldnews
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Bayer signed an agreement Thursday to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines. more
-
2013-05-16 | Cancer
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
2013-05-16 | Cancer
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more
-
2013-05-15 | Cancer
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
2013-05-15 | Cancer
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival more





